share_log

Does Jiangsu Yuyue Medical Equipment & Supply (SZSE:002223) Have A Healthy Balance Sheet?

Does Jiangsu Yuyue Medical Equipment & Supply (SZSE:002223) Have A Healthy Balance Sheet?

江蘇裕越醫療設備及供應有限公司(SZSE:002223)的資產負債表健康嗎?
Simply Wall St ·  06/10 02:46

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. As with many other companies Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SZSE:002223) makes use of debt. But the more important question is: how much risk is that debt creating?

David Iben說得好,“波動性並不是我們關心的風險。我們關心的是避免永久性的資本損失。”因此,明智的錢知道債務-通常涉及破產-是評估公司風險的一個非常重要的因素。就像許多其他公司一樣,江蘇裕越醫療器材供應股份有限公司(SZSE: 002223)利用債務。但更重要的問題是:那些債務帶來了多少風險?

When Is Debt A Problem?

什麼時候負債才是一個問題?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first step when considering a company's debt levels is to consider its cash and debt together.

當一個公司難以通過自由現金流或以有吸引力的價格籌集資金來輕鬆兌現債務時,負債和其他負擔對其構成風險。如果形勢異常糟糕,貸方可能會控制公司。然而,更頻繁但同樣代價高昂的情況是公司必須以低價發佈股票以穩定其資產負債表,從而永久性地稀釋股東的權益。當然,許多公司借債資金進行擴張,沒有任何負面後果。考慮公司的債務水平時的第一步是將其現金和債務合併考慮。

What Is Jiangsu Yuyue Medical Equipment & Supply's Net Debt?

江蘇裕越醫療器材供應的淨債務是什麼?

The image below, which you can click on for greater detail, shows that Jiangsu Yuyue Medical Equipment & Supply had debt of CN¥1.00b at the end of March 2024, a reduction from CN¥1.49b over a year. But it also has CN¥7.66b in cash to offset that, meaning it has CN¥6.65b net cash.

如下圖所示(點擊可放大),江蘇裕越醫療器材供應在2024年3月底的債務爲10億元人民幣,較去年的14.9億元人民幣減少。但它還有76.6億元人民幣的現金來彌補這個問題,這意味着它有66.5億元人民幣的淨現金。

debt-equity-history-analysis
SZSE:002223 Debt to Equity History June 10th 2024
SZSE:002223股權與負債歷史記錄2024年6月10日

How Strong Is Jiangsu Yuyue Medical Equipment & Supply's Balance Sheet?

江蘇裕越醫療器材供應的財務狀況如何?

We can see from the most recent balance sheet that Jiangsu Yuyue Medical Equipment & Supply had liabilities of CN¥3.05b falling due within a year, and liabilities of CN¥965.2m due beyond that. Offsetting these obligations, it had cash of CN¥7.66b as well as receivables valued at CN¥1.07b due within 12 months. So it actually has CN¥4.71b more liquid assets than total liabilities.

我們可以從最新的財務狀況表中看到,江蘇裕越醫療器材供應有305億元人民幣的負債在一年內到期,而後面還有96520萬元的負債。抵消這些義務,它有766億元人民幣的現金以及105億元人民幣的應收賬款在12個月內到期。所以它實際上有471億元人民幣。總負債還多出了更多的流動資產。

This surplus suggests that Jiangsu Yuyue Medical Equipment & Supply has a conservative balance sheet, and could probably eliminate its debt without much difficulty. Succinctly put, Jiangsu Yuyue Medical Equipment & Supply boasts net cash, so it's fair to say it does not have a heavy debt load!

這個盈餘表明,江蘇裕越醫療器材供應擁有穩健的資產負債表,很可能可以輕鬆消除其債務。簡言之,江蘇裕越醫療器材供應擁有淨現金,因此沒有沉重的債務負擔!

Also good is that Jiangsu Yuyue Medical Equipment & Supply grew its EBIT at 11% over the last year, further increasing its ability to manage debt. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if Jiangsu Yuyue Medical Equipment & Supply can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

江蘇裕越醫療器材供應去年EBIT增長11%,這也是好的,進一步增加了其管理債務的能力。毫無疑問,我們從資產負債表中了解到債務最多。但最終業務的未來盈利能力將決定江蘇裕越醫療器材供應能否隨着時間推移增強其資產負債表。因此,如果您關注未來,可以查看此免費報告,顯示分析師的利潤預測。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. Jiangsu Yuyue Medical Equipment & Supply may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Over the last three years, Jiangsu Yuyue Medical Equipment & Supply actually produced more free cash flow than EBIT. That sort of strong cash generation warms our hearts like a puppy in a bumblebee suit.

但是我們的最終考慮也很重要,因爲公司不能用紙上利潤付債務;它需要冰冷的現金。江蘇裕越醫療器材供應在資產負債表上有淨現金,但是看看它的收益前利息和稅前利潤(EBIt)與自由現金流的轉換有多好,因爲這將影響其管理債務的需求和能力。在過去的三年中,江蘇裕越醫療器材供應實際上產生的自由現金流比EBIt還要多一些。這種強勁的現金生成方式讓我們感到溫馨,就像一個穿着大黃蜂衣服的小狗狗。

Summing Up

總之

While it is always sensible to investigate a company's debt, in this case Jiangsu Yuyue Medical Equipment & Supply has CN¥6.65b in net cash and a decent-looking balance sheet. The cherry on top was that in converted 108% of that EBIT to free cash flow, bringing in CN¥1.9b. So is Jiangsu Yuyue Medical Equipment & Supply's debt a risk? It doesn't seem so to us. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. We've identified 2 warning signs with Jiangsu Yuyue Medical Equipment & Supply , and understanding them should be part of your investment process.

雖然調查公司的債務總是明智的,但在這種情況下,江蘇裕越醫療器材供應有665億元人民幣的淨現金和一個看起來不錯的財務狀況。更棒的是它將108%的EBIt轉換爲自由現金流,帶來19億元人民幣。那麼江蘇裕越醫療器材供應的債務是風險嗎?我們不這麼認爲。在分析債務水平時,資產負債表是顯而易見的起點。但是,最終,每個公司都可能存在超出資產負債表範圍的風險。我們已經確定了江蘇裕越醫療器材供應的2個警告信號,了解它們應該成爲您的投資過程的一部分。

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

如果您有興趣投資能夠在不負債的情況下增長利潤的企業,請查看這份免費列表,其中列出了在資產負債表上擁有淨現金的成長型企業。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論